期刊
EUROPEAN JOURNAL OF CANCER
卷 46, 期 18, 页码 3365-3374出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2010.07.007
关键词
Apigenin; p53; p21; NAG-1; PKG delta; Colorectal cancer
类别
资金
- American Cancer Society [CNE-111611]
- National Institutes of Health [R01CA108975]
- University of Tennessee, Center of Excellence in Livestock Diseases and Human Health
- Shanghai Municipal Education Commission, China [07CZ022]
- Royal Golden Jubilee PhD Program, Thailand [PHD/0245/2545, PHD/0159/2546]
- NATIONAL CANCER INSTITUTE [R01CA108975] Funding Source: NIH RePORTER
Persuasive epidemiological and experimental evidence suggests that dietary flavonoids have anti-cancer activity. Since conventional therapeutic and surgical approaches have not been able to fully control the incidence and outcome of most cancer types, including colorectal neoplasia, there is an urgent need to develop alternative approaches for the management of cancer. We sought to develop the best flavonoids for the inhibition of cell growth, and apigenin (flavone) proved the most promising compound in colorectal cancer cell growth arrest. Subsequently, we found that pro-apoptotic proteins (NAG-1 and p53) and cell cycle inhibitor (p21) were induced in the presence of apigenin, and kinase pathways, including PKC delta and ataxia telangiectasia mutated (ATM), play an important role in activating these proteins. The data generated by in vitro experiments were confirmed in an animal study using APC(MIN+) mice. Apigenin is able to reduce polyp numbers, accompanied by increasing p53 activation through phosphorylation in animal models. Our data suggest apparent beneficial effects of apigenin on colon cancer. (c) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据